Sarepta Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Sarepta Therapeutics 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About SRPT

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA. 

CEO
Douglas S. Ingram
CEODouglas S. Ingram
Employees
1,372
Employees1,372
Headquarters
Cambridge, Massachusetts
HeadquartersCambridge, Massachusetts
Founded
1980
Founded1980
Employees
1,372
Employees1,372

SRPT Key Statistics

Market cap
2.13B
Market cap2.13B
Price-Earnings ratio
-7.03
Price-Earnings ratio-7.03
Dividend yield
Dividend yield
Average volume
3.04M
Average volume3.04M
High today
High today
Low today
Low today
Open price
$21.18
Open price$21.18
Volume
0.00
Volume0.00
52 Week high
$129.84
52 Week high$129.84
52 Week low
$10.42
52 Week low$10.42

Stock Snapshot

With a market cap of 2.13B, Sarepta Therapeutics(SRPT) trades at $20.41. The stock has a price-to-earnings ratio of -7.03.

On 2025-12-19, Sarepta Therapeutics(SRPT) shares started trading at $21.18, with intraday highs of — and lows of —.

Trading volume for Sarepta Therapeutics(SRPT) stock has reached 0, versus its average volume of 3.04M.

The stock's 52-week range extends from a low of $10.42 to a high of $129.84.

The stock's 52-week range extends from a low of $10.42 to a high of $129.84.

SRPT News

Simply Wall St 23h
Will FDA Liver Warning and Newborn Screening Expansion Change Sarepta Therapeutics' Risk‑Reward Narrative?

Sarepta Therapeutics recently executed a convertible notes exchange to ease near-term refinancing pressure and extend its cash runway, while the FDA updated the...

Will FDA Liver Warning and Newborn Screening Expansion Change Sarepta Therapeutics' Risk‑Reward Narrative?
TipRanks 6d
Vertiv, Affirm, Sarepta, Micron, PepsiCo: Trending by Analysts

Analysts are intrested in these 5 stocks: ( (VRT) ), ( (AFRM) ), ( (SRPT) ), ( (MU) ) and ( (PEP) ). Here is a breakdown of their recent ratings and the rationa...

Analyst ratings

54%

of 26 ratings
Buy
26.9%
Hold
53.8%
Sell
19.2%

People also own

Based on the portfolios of people who own SRPT. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.